Teva Pharmaceuticals (three generic drugs) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Teva Pharmaceuticals (three generic drugs) General Information

Description

A portfolio of rights to three generic drugs. The portfolio is for ownership of the abbreviated new drug applications (ANDAs) for fentanyl citrate lozenges, which are the generic version of Actiq; cyclobenzaprine ER capsules, the generic version of Amrix. as well as the U.S. rights to market modafinil tablets the generic version of Provigil.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Primary Office
  • 5 Bazel Street
  • Petach Tikva 49131
  • Israel
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Teva Pharmaceuticals (three generic drugs) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Teva Pharmaceuticals (three generic drugs)‘s full profile, request access.

Request a free trial

Teva Pharmaceuticals (three generic drugs) Executive Team (1)

Name Title Board Seat Contact Info
Yael Rabin Associate Director, Global Business Development & Strategy - M&A Team
To view Teva Pharmaceuticals (three generic drugs)’s complete executive team members history, request access »

Teva Pharmaceuticals (three generic drugs) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Teva Pharmaceuticals (three generic drugs)‘s full profile, request access.

Request a free trial